Bilirubin, a potent endogenous antioxidant, was found to protect against development of diabetic nephropathy (DN) in rodents. In humans, cross-sectional studies found an inverse relation between bilirubin and DN. We prospectively investigated whether bilirubin is associated with progression of DN towards end-stage renal disease (ESRD). To this end, we performed a post-hoc analysis in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial with independent replication in the Irbesartan Diabetic Nephropathy Trial (IDNT). Subjects with type 2 diabetes and nephropathy with ALT, AST, and bilirubin levels <1.5 times the ULN were included. The renal endpoint was defined as the composite of confirmed doubling of serum creatinine (DSCR) or ESRD.
Introduction
The incidence of type 2 diabetes and its complications are increasing worldwide. One of the major complications of type 2 diabetes is diabetic nephropathy. Approximately 20 to 40% of patients with diabetes develop nephropathy, which is the single leading cause of end-stage renal disease (ESRD) around the world (1).
Bilirubin is a product of heme catabolism and is known to be a potent endogenous antioxidant (2) . As such, bilirubin has consistently been associated with protection against development of cardiovascular disease (3, 4) . A recent study in rodents suggested that bilirubin is also protective against progression of diabetic nephropathy (5) . This notion was supported by several cross-sectional studies in humans demonstrating that low levels of bilirubin are associated with diabetic nephropathy (6) (7) (8) .
However, to our knowledge, to date there are no prospective studies that have investigated whether bilirubin levels are associated with progression of diabetic nephropathy towards ESRD. Therefore, our primary objective was to prospectively investigate the association of bilirubin with progression of nephropathy in patients with type 2 diabetes. To this end, we performed a historical prospective study in the Reduction of Endpoints in NonInsulin-dependent Diabetes with the Angiotensin II Antagonist Losartan (RENAAL) trial (9,
Measurements and Clinical Endpoints
Laboratory and physical assessment data were collected every 6 months during follow-up for subjects participating in RENAAL and IDNT respectively and included blood pressure measurements, glycated hemoglobin (HbA 1c ), lipid profile, hemoglobin, total bilirubin, serum albumin, ALT, AST, and serum creatinine (SCr). For both trials, all biochemical measurements were conducted in a central laboratory according to standardized conditions. Estimated glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula (17). The primary endpoint for the present study was the composite of a confirmed doubling of baseline serum creatinine level (DSCR) or ESRD (defined as the need for chronic dialysis or renal transplantation). All endpoints were adjudicated by an independent adjudication committee using rigorous guidelines and definitions.
Statistical analyses
Statistical analyses were performed using SPSS version 18.0 for Windows (SPSS inc., Chicago, Illinois, USA) and STATA version 11 (StataCorp., College Station, TX: StataCorp LP). Results are presented as mean ± standard deviation (SD) for variables with a normal distribution and as median [interquartile range] for variables with a non-normally distribution.
Nominal data are presented as the total number of patients with percentages. A two-sided p<0.05 was considered to indicate statistical significance.
To assess which baseline variables were associated with baseline total bilirubin, the study populations were subdivided in tertiles of baseline total bilirubin concentration, and patient characteristics were presented accordingly ( Table 1) . P-values for trend across tertiles of baseline total bilirubin were assessed using linear regression analyses. Variables with a skewed distribution were log-transformed to fulfill criteria for linear regression analyses.
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The course of clinical parameters over time are presented according to tertiles of baseline bilirubin (Supplementary Table S2 ). We investigated whether the change in total bilirubin over time differed between tertiles of bilirubin in subjects with complete bilirubin measurements at baseline, 12, 24, and 36 months using one-way ANOVA (Supplementary Table S3 ).
To investigate the association of total bilirubin with progression of nephropathy, we used Cox proportional hazard regression analyses with time-varying covariates, which takes the change of clinical parameters over time into account (Table 3) . Logarithmic transformation (base 2) of bilirubin levels was applied in order to present the hazard ratios derived from Cox regression analyses per doubling of bilirubin levels. Multivariable analyses were conducted using a Cox regression model including the potential confounding factors age, sex, baseline eGFR, baseline log ACR, race, smoking at baseline, history of CVD at baseline, baseline BMI, total cholesterol, diastolic blood pressure, HbA 1c , treatment assignment, and log AST.
As sensitivity analyses, we repeated the Cox regression analyses in the subgroups receiving an ARB (i.e. losartan in RENAAL and irbesartan in IDNT) or placebo in both trials.
As further sensitivity analyses, we investigated whether the change in bilirubin values during the course of the trials was associated with renal progression.
To investigate the effect of treatment with an ARB on serum concentrations of hemoglobin and total bilirubin, we used the independent sample t-test to compare hemoglobin and bilirubin concentrations between treatment groups in both trials ( Figure 2 ).
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Results
Patient Characteristics
In RENAAL, bilirubin concentrations were available for 1,498 (99.0%) patients. Mean baseline bilirubin level was 0.57 ± 0.19 mg/dL. Baseline patient characteristics according to tertiles of baseline bilirubin levels are presented in Table 1 . Prevalence of male gender, age, history of CVD, hemoglobin, serum albumin, liver enzymes, and eGFR increased with increasing bilirubin levels, while the use of diuretics, use of insulin, BMI, HbA 1c , cholesterol, triglycerides, and urinary albumin-to-creatinine ratio (ACR) decreased with increasing bilirubin levels. Multivariable linear regression analyses showed that baseline bilirubin levels were independently associated with age, smoking, BMI, HbA 1c , hemoglobin, serum albumin, log AST, and total cholesterol (Table 2 ).
In IDNT, bilirubin concentrations were available for 1,707 patients (99.5%). Mean baseline bilirubin level in IDNT was similar to that in RENAAL (0.54 ± 0.21 mg/dL). In general, associations and trends of bilirubin with baseline characteristics were similar to those observed in RENAAL. In multivariable linear regression analyses, all variables that were independently associated with bilirubin in RENAAL (except AST) were also independently associated with bilirubin in IDNT. Gender, race, diastolic blood pressure, duration of diabetes (≥5 years), and eGFR were additional variables that were significantly associated with bilirubin levels in IDNT.
Clinical parameters over time
The course of clinical parameters over time is shown in Supplementary Table S2. In RENAAL, the change in total bilirubin concentration only differed between tertiles of baseline bilirubin at 12 months. After 24 and 36 months, there were no significant differences Table S3 ).
These results were confirmed in IDNT (Supplementary Table S3 ).
Progression of nephropathy
After a mean follow-up period of 3.4 years, a total of 471 (31%) subjects had reached the renal endpoint of doubling of serum creatinine (DSCR) Figure 1A . (Table 3 ). The graph indicating the risk for the renal endpoint according to total bilirubin concentrations in IDNT is similar to the graph of the risk of the renal endpoint in RENAAL ( Figure 1B) .
In sensitivity analyses, we investigated whether total bilirubin was associated with progression of nephropathy irrespective of ARB or placebo assignment. In RENAAL, total bilirubin was significantly and inversely associated with progression of nephropathy both for 
Angiotensin Receptor Blocker Treatment Effect
Since treatment with ARBs influence serum concentrations of hemoglobin (13), and could consequently affect bilirubin levels, we investigated the effect of treatment with an ARB (losartan in RENAAL and irbesartan in IDNT) on serum concentrations of hemoglobin and bilirubin.
Hemoglobin and bilirubin concentrations over time in the RENAAL trial are shown in Figure 2A and 2B respectively. Hemoglobin levels slowly decreased over time in the placebo group, while an initial decrease followed by a stabilization of hemoglobin levels was seen in losartan treated patients ( Figure 2A ). After 48 months of treatment, hemoglobin levels were no longer significantly different between treatment groups ( Figure 2A ).
Bilirubin levels were slightly, but not significantly, lower in the losartan group compared to the placebo group ( Figure 2B ). Despite the initial fall in hemoglobin levels, there was no initial fall in bilirubin levels in the losartan group. Bilirubin values decreased over time in both treatment groups, and no significant differences in bilirubin concentrations were observed between treatment groups after 12, 36, and 48 months. Figure 2C and 2D respectively. In general, the pattern of changes in these markers over time in IDNT was similar as in RENAAL. Although hemoglobin levels significantly decreased after initiation of treatment with irbesartan ( Figure 2C ), as in RENAAL, no significant differences in bilirubin concentrations were observed between treatment groups ( Figure 2D ).
Discussion
In this historical prospective analysis of the RENAAL trial, we found an independent inverse association of bilirubin levels with progression of nephropathy in patients with type 2 diabetes. This finding was independently replicated in the IDNT trial. Furthermore, we showed that treatment with the ARBs losartan or irbesartan did not result in a decrease in bilirubin concentrations, despite an initial decrease in hemoglobin levels.
One of the major pathophysiologic mechanisms that has been identified in the development and progression of diabetic nephropathy is oxidative stress, described as increased levels of reactive oxygen species (ROS) (18-20). Bilirubin is known to be a potent endogenous antioxidant (2) , and a recent study in rodents found a protective effect of bilirubin against diabetic nephropathy through inhibition of oxidative stress by down regulation of renal nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (5). In addition, it was shown that bilirubin levels were higher in patients without diabetic nephropathy than in patients with diabetic nephropathy (7).
However, these studies were cross-sectional in design, precluding investigation of the prospective association of bilirubin with renal impairment. To our knowledge, this is the first prospective study to indicate an inverse association of bilirubin and progression of nephropathy towards ESRD in type 2 diabetes.
In animal models, antioxidants have been shown to be effective in treating diabetic nephropathy (21, 22). In combination with our human data showing an independent association between bilirubin and renal outcome, we speculate that treatments intended to slightly raise bilirubin levels might have a beneficial effect on progression of nephropathy in patients with type 2 diabetes and low bilirubin levels.
A moderate increase in bilirubin levels could be attained through induction of heme oxygenase-1 (HO-1), the enzyme that catalyzes the rate-limiting step in heme degradation.
HO-1 splits heme into carbon monoxide (CO) and biliverdin, which is subsequently reduced to bilirubin (2, 23). The HO-1 system and heme degradation products CO, biliverdin, and bilirubin have repeatedly been shown to have renoprotective properties (2, 23) . It is, therefore, possible that the renoprotective effects of bilirubin in this study are, at least partly, mediated by induction of HO-1 and by-products of heme degradation (i.e. CO and biliverdin). In rats, a recent study showed that induction of HO-1 reduces renal oxidative stress and protects against diabetes-related renal injury (24). HO-1 is a highly inducible enzyme, which can be induced by many drugs routinely used in clinical medicine (i.e. non-steroidal anti-inflammatory drugs Second, in both RENAAL and IDNT, only total bilirubin was measured. Direct (conjugated) bilirubin was not measured separately because serum bilirubin consists for >95% of indirect (unconjugated) bilirubin (26) and subjects with total bilirubin levels >1.5 times the ULN were excluded from participation in both trials. It was, therefore, not possible to examine differences between unconjugated and conjugated bilirubin levels. Furthermore, given the observational nature of this study and the inability to focus on the HO-1 system and its byproducts in more detail, it is impossible to draw a definitive conclusion about the causality of bilirubin and progression of diabetic nephropathy. Mendelian randomization has been proposed as a method which enables estimation of causal relationships in observational studies (31, 32). This method utilizes genotype to estimate causal relationships between a gene product and physiological outcomes (32). Since there is a strong relation between UGT1A1 (genotype) and bilirubin levels (phenotype) (32), mendelian randomization can be used to establish a possible causal relation between bilirubin and diabetic nephropathy.
Strengths of this study are the large sample size, the large number of renal events, and the independent replication of our findings in another large cohort of over 1,700 subjects.
In conclusion, our results show an independent inverse association of bilirubin levels with progression of nephropathy in patients with type 2 diabetes. This suggests that measurement of bilirubin may identify subjects at risk for renal disease progression. In addition, our study suggests a protective effect of bilirubin against progression of diabetic nephropathy, hereby potentially implying its role as an antioxidant. 
Laboratory measurements
Hemoglobin (g/dL) 12.5 ± 1.8 11.6 ± 1.5 12.5 ± 1.7 13.5 ± 1.8 <0.001 12.9 ± 1.9 12.0 ± 1.8 12.9 ± 1.8 13.8 ± 1.7 <0.001
Serum albumin (g/dL) 3.8 ± 0. Serum creatinine (mg/dL) 1.9 ± 0.5 1.9 ± 0.5 1.9 ± 0.5 1.8 ± 0.4 <0.001 1.7 ± 0.6 1.8 ± 0.6 1.7 ± 0.6 1.6 ± 0. 
